Hydroxytyrosol

Summary

Hydroxytyrosol (CHEMBL1950045) is a phase-3 clinical-stage small-molecule antineoplastic agent; indicated across 1 condition including breast neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 10
• Chemistry: 154.16 Da · C8H10O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1950045
Name	Hydroxytyrosol
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	82755
ChEBI	CHEBI:68889
Molecular formula	C8H10O3
Molecular weight	154.16
InChIKey	JUUBCHWRXWPFFH-UHFFFAOYSA-N

SMILES: C1=CC(=C(C=C1CCO)O)O

IUPAC name: 4-(2-hydroxyethyl)benzene-1,2-diol

ChEBI definition: A member of the class of catechols that is benzene-1,2-diol substituted by a 2-hydroxyethyl group at position 4. Isolated from Olea europaea, it exhibits antioxidant and antineoplastic activities.

Pharmacological roles (ChEBI): antioxidant, antineoplastic agent.

Other ChEBI roles (chemical / environmental): metabolite.

Also known as: Homoprotocatechuyl alcohol, Hydroxytyrosol, SID24841446, hydroxytyrosol, HYDROXYTYROSOL

Patent coverage: 2,729 distinct patent families (6,641 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 6,577 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Microtubule-associated protein tau, Lysine-specific demethylase 4E, 4’-phosphopantetheinyl transferase ffp, Polyunsaturated fatty acid 5-lipoxygenase, Lysosomal alpha-glucosidase, Aldehyde dehydrogenase 1A1, Beta-secretase 1.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
BACE1	7.46	IC50	35	nM	CHEMBL_ACT_25030894

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
breast neoplasm	2	MONDO:0021100	MONDO:0007254

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
Not specified	8
PHASE2/PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02068092	PHASE2/PHASE3	COMPLETED	Olive Oil for High Risk Breast Cancer Prevention in Women
NCT06833866	PHASE1	RECRUITING	Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer
NCT07298759	Not specified	ACTIVE_NOT_RECRUITING	The Effect of Hydroxytyrosol Administration on Superoxide Dismutase, Pulsatility Index and Resistance Index of Uterine Artery Doppler and Flow-Mediated Dilatation of Brachial Artery In Mothers With Hypertension In Pregnancy
NCT01983943	Not specified	WITHDRAWN	Olive Oil and Cardiovascular Health
NCT02273622	Not specified	COMPLETED	Human Study of Hydroxytyrosol on Phase II Enzymes in Healthy Subjects
NCT04317079	Not specified	COMPLETED	Effects of Hydroxytyrosol Administration in Anthropometric Parameters in Overweight and Obese Women
NCT04876261	Not specified	COMPLETED	Bioavailability of Hydroxytyrosol From Olive Watery Extract Supplements
NCT05679310	Not specified	COMPLETED	Innovative Biotechnological Production of Antioxidant Products
NCT06735222	Not specified	COMPLETED	Bioavailability of Hydroxytyrosol in Humans Co-administered With EPA
NCT07074548	Not specified	COMPLETED	Effect of Hydroxytyrosol on NLR, MLR, and SOD in Hypertensive Pregnant Women

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).